Evidence map›Paper›PMID 30842299›Full record

ArticleNeurology2019

The prognostic value of ATN Alzheimer biomarker profiles in cognitively normal individuals.

Stephanie J B Vos, Ranjan Duara

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Neurology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2021
    Article
  8. Article
  9. Article
  10. Quantitative MRI Differences Between Early versus Late Onset Alzheimer's Disease.American journal of Alzheimer's disease and other dementias
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Stephanie J B VosFrom the Department of Psychiatry and Neuropsychology (S.J.B.V.), School for Mental Health and NeuroScience, Alzheimer Center Limburg, Maastricht University, the Netherlands; Wien Center for Alzheimer's Disease and Memory Disorders (R.D.), Mount Sinai Medical Center, Miami Beach; and Department of Neurology (R.D.), University of Florida College of Medicine, Gainesville. s.vos@maastrichtuniversity.nl.
Ranjan DuaraFrom the Department of Psychiatry and Neuropsychology (S.J.B.V.), School for Mental Health and NeuroScience, Alzheimer Center Limburg, Maastricht University, the Netherlands; Wien Center for Alzheimer's Disease and Memory Disorders (R.D.), Mount Sinai Medical Center, Miami Beach; and Department of Neurology (R.D.), University of Florida College of Medicine, Gainesville.

Funding

University of Florida - Mt. Sinai Medical Center AD Research CenterP50AG047266 · NIA · UNIVERSITY OF FLORIDA · PI LOEWENSTEIN, DAVID · 2015 to 2019
$7.3M
NIA NIH HHS P50 AG047266
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesBiomarkersCognitionHumansPrognosisAmyloid beta-PeptidesBiomarkers

Identifiers

PMID30842299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.